来自:中国糖尿病杂志 编辑:侯文芳 肖文华 洪天配|点击数:|2013-07-18
·文献综述·
【摘要】 噻唑烷二酮(TZDs)类药物是近年来常用的一类口服降糖药,其可能会对糖尿病患者的骨代谢产生不良影响,使骨密度下降,甚至导致骨折风险增加。本
文就TZDs类药物对糖尿病患者骨代谢的影响及其可能机制进行综述。
【关键词】噻唑烷二酮类药物;2型糖尿病;骨代谢
The effects and mechanisms of thiazolidinediones on bone metaborism in the
patients with type 2 diabetes Hou Wen-Fang, Xiao,Wen-Hua Hong Tian-Pei
Department of Endocrinology, Peking University Third Hospital。Beijing 100191,China
【Abstract】 Thiazolidinediones (TZDs) , selective agonists of peroxisome proliferator-activated receptor gamma , are kinds of oral anti-diabetic drugs. Several large-scale clinical trials have reported that TZDs may contribute to decreased bone mineral density and increased risk of fracture. In this article, we review the effects and mechanisms of thiazolidinediones on bone metabolism in the patients with type 2 diabetes.
【Key words】 Thiazolidinediones; Diabetes mellitus,Type 2; Bone metabolism
版权所有:《中国糖尿病杂志》社 主管单位:中华人民共和国教育部 主办单位:北京大学
地址:北京市西城区大红罗厂街1号 邮编:100034 电话(传真):010-88505683
中国糖尿病杂志社版权所 京ICP备11029051号-1 Powered by JiuduCMS 技术支持:九度创想